Stryker revealed this week that it has signed a definitive agreement to acquire Amplitude Vascular Systems (AVS), which is developing a next-generation intravascular lithotripsy (IVL) platform designed to treat calcified peripheral arterial disease (PAD).
A press release notes that the acquisition will strengthen Stryker’s peripheral vascular portfolio by adding revascularisation technology. Once cleared for use in applicable markets, the product will complement Stryker’s existing peripheral vascular offerings and support the company’s strategy to expand its presence in arterial disease treatment.
“This acquisition represents an important step in advancing our vision to build a comprehensive peripheral vascular platform and address significant unmet clinical needs,” said Kevin Lobo, chair and CEO, Stryker. “Combining this innovation with Stryker’s scale and clinical expertise, we believe we can help expand treatment options for physicians and improve care for patients with calcified peripheral arterial disease.”
AVS’ technology is designed to use pulsed CO₂-generated pressure waves uniformly delivered through an IVL balloon catheter, to fracture calcium and optimise luminal gain. The platform is designed to enhance catheter deliverability, treatment speed and therapy efficiency.
This transaction is subject to customary closing conditions. Stryker and AVS will continue to operate as separate entities and proceed with business as usual until the transaction closes.
